Leadership

Boris Weiss
Chief Executive Officer

Throughout his business career, Mr. Weiss has driven his corporate success through effective economic, financial and business modeling, strategic planning and program execution, global market development and relationship networking with government, industry and investors.

Mr. Weiss has been instrumental in the development and roll out of a number of integral biomedical and biotech ventures. Specific achievements included establishing the strategic direction of non-invasive technologies for a variety of health problems, including the acquisition of an exclusive worldwide technology license to commercialize a transurethral stent.

Mr. Weiss spent five years partnered with an international, high-tech research and development company to establish North American business operations and aggressively market patented photonic and material technologies. In this role, he managed the acquisition and construction of a new state-of-the-art research facility, overcame governmental policy challenges, and facilitated the immigration of key scientific personnel within a tight timeframe. In this role Mr. Weiss established government relations at the provincial and federal levels to secure research funding, and built an advocacy network with thought leaders.

His combined extensive experience in business and market development with proven achievement in strategic consulting, corporate governance, and organizational leadership, provide a multidimensional approach with a talent for overcoming challenges to diversify revenue streams, increase shareholder wealth and move an organization forward within a global market context.

June Update:

Dr. Nihar R. Pandey
Chief Scientific Officer

Dr. Pandey is our Chief Scientific Officer (CSO), he also serves in similar role for CliniCan Health Research. He is PhD in Clinical Biochemistry with expertise in clinical and regulatory affairs and did his postdoctoral studies at University of Montreal and at McGill University. He was a Group leader for Drug Discovery and development at Liponex Inc., Ottawa. He worked as Research Scientist at University of Ottawa Heart Institute, Ottawa Hospital Research Institute (OHRI)-Neuroscience, University of Ottawa and at Health Canada. He has extensive life sciences and pharma experience in the discovery, development, drug formulation, clinical trials and commercialization of drugs. His career highlights include the development of inhibitors for the treatment of metabolic disorders, anxiety, learning impairments, and neurodegeneration. His accomplishments include more than 30 scientific publications, 5 patents, a book chapter, and several abstracts. He is a member of several international and national professional societies and institutes, and serves in editorial boards and as a scientific reviewer in high-impact medical/biomedical journals. Dr. Pandey is responsible for promoting leading edge research, including collaborative and interdisciplinary research in cannabinoid-based product development. This role works to develop networks between Medipure and industry researchers in the public and private sectors locally, nationally, and internationally. He will act as a nexus between Medipure and the physician community with respect to research and clinical initiatives of mutual benefit. In addition, Dr. Pandey will lead Medipure Scientific and R&D programs. He has a strong background in pharmaceutical development processes and experience in clinical monitoring, bringing significant experience in the conduct/management of Phase I and II clinical trials. His working knowledge of physiology and pharmacology and excellent knowledge of applicable Canadian, US, and international regulations and guidelines, will allow Medipure to effectively manage clinical development and data collection in all co-directed clinical trials, including the oversight of adverse event reporting, adherence to protocols, and ensuring successful study completion. For the last 20 years, he is actively involved in pharmaceutical development, associated with Diabetes, Cardiovascular diseases, Pain, Mood disorders, Oncology and Neurodegeneration. He is considered one of the leaders in drug discovery and development associated with these diseases.

Dr. John Maynard
Medical Director

Dr. John Maynard brings more than 44-years of clinical and leadership experience to the Medipure team.

After graduating from the University of Calgary’s Medical school, Dr. Maynard did a two-year internship in Victoria, followed by 10-years of Emergency Medicine in both Victoria and Vancouver. It was at Royal Jubilee Hospital in Victoria that Dr. Maynard was also involved as Director of Internship. He also served as the Canadian Association of Emergency Medicine continuing medical education committee chairman and Co- Medical Director for Expo 86.

Dr. Maynard moved on to full-service family practice in North Vancouver and during more than 24 years of family practice, he served as Department Head at Lions Gate Hospital, Chief of Staff, and as a physician board member for the North Shore Health Region.

When the Vancouver Coastal Health Authority was established, Dr. Maynard was appointed as Co-Senior Medical Director, overseeing medical care in six facilities as well as Director of Risk Management and Patient Safety. During this time, Vancouver hosted the Winter Olympics and Dr. Maynard served on the committee responsible for ensuring appropriate Medical Care for Athletes and Visitors. After leaving his Family Practice to assume the above duties, Dr. Maynard continued to provide clinical care in an urgent care setting.

Dr. Maynard subsequently served as a member of the Senior Executive Team of Vancouver Coastal Health and was appointed Chairman of the Authority’s Medical Advisory Committee.

Dr. Maynard’s extensive clinical experience as an emergency physician and full-service family physician, combined with his outstanding administrative background within the medical community both provincially and federally, provides Medipure a conduit to the physician community and to government bodies nationwide.

Alan Mendelson
Corporate Secretary and Advisor to the Board of Directors

Alan C. Mendelson, of the firm Latham & Watkins, represents emerging and public growth companies primarily in the life-sciences industry. He has managed and supervised a variety of major business transitions including public offerings.

Mr. Mendelson has served as the Co-Chair of Latham & Watkins Emerging Companies Practice from 2010 to 2013 and is currently Co-Chair of the Life Sciences Industry Group.

Honorable Lorne Nystrom, Privy Councilor
Director

A Saskatchewan native, Lorne was elected nine times as a Saskatchewan Member of Parliament first in Yorkton-Melville then Regina–Qu’Appelle serving for 32 years. When first elected in 1968 Lorne was the youngest Canadian ever elected to Parliament at age 22. In 1992 he was appointed a member of the Privy Council, of Canada, a life-long position by Her Majesty Queen Elizabeth II.

As a Parliamentarian, Lorne specialized in economic and constitutional issues and gained extensive experience with both foreign affairs and trade issues. He was a member of several international Canadian Parliamentary delegations. Lorne was a spokesperson on the Canadian Constitution during the debates on the 1982 Constitution Act that led to partition, and adoption of the Charter of Rights and Freedoms including the entrenchment of treaty rights in the Constitution.

Lorne's international experience includes projects with Harvard University in Russia and with the United Nations in South Africa, bringing expertise with government regulatory and compliance issues in Canada and internationally. His business background includes extensive experience in China. Lorne speaks both English and French.